These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24400802)

  • 1. Vitamin K antagonists: beyond bleeding.
    Krüger T; Floege J
    Semin Dial; 2014; 27(1):37-41. PubMed ID: 24400802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban.
    Barrios V; Górriz JL
    J Comp Eff Res; 2015 Nov; 4(6):651-64. PubMed ID: 26388302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.
    Liew A; Eikelboom JW; O'Donnell M; Hart RG
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S34-44. PubMed ID: 23790596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulants, renal failure and atrial fibrillation.
    Genovesi S; Santoro A
    Expert Opin Drug Saf; 2013 Jan; 12(1):1-3. PubMed ID: 23163428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bleeding during anti-vitamin K treatment. Incidence, risk factors and comparison with the new oral anticoagulants].
    Korin J
    Medicina (B Aires); 2012; 72(5):419-24. PubMed ID: 23089119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulants in patients with atrial fibrillation and end-stage renal disease.
    Brimble KS; Ingram AJ; Eikelboom JW; Hart RG
    Postgrad Med; 2012 Nov; 124(6):17-25. PubMed ID: 23322135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated guidelines on outpatient anticoagulation.
    Wigle P; Hein B; Bloomfield HE; Tubb M; Doherty M
    Am Fam Physician; 2013 Apr; 87(8):556-66. PubMed ID: 23668445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New treatments for stroke and thromboembolism prevention in atrial fibrillation].
    Shiyovich A; Khalameizer V; Katz A
    Harefuah; 2014 Jan; 153(1):32-8, 64. PubMed ID: 24605405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New antithrombotics for atrial fibrillation].
    Verheugt F
    Ned Tijdschr Geneeskd; 2011; 155():A2143. PubMed ID: 21291575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation.
    Tincani E; Baldini P; Crowther MA; Zanasi A; Ferrari P; Cenci AM; Rioli G
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):47-51. PubMed ID: 20523164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated international normalized ratio from vitamin K supplement discontinuation.
    Miesner AR; Sullivan TS
    Ann Pharmacother; 2011 Jan; 45(1):e2. PubMed ID: 21205949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?
    Fiaccadori E; Maggiore U; Regolisti G
    Nephrol Dial Transplant; 2013 Dec; 28(12):2923-8. PubMed ID: 24026242
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacologic Therapies in Anticoagulation.
    Ferreira JL; Wipf JE
    Med Clin North Am; 2016 Jul; 100(4):695-718. PubMed ID: 27235611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.
    Dentali F; Pignatelli P; Malato A; Poli D; Di Minno MN; Di Gennaro L; Rancan E; Pastori D; Grifoni E; Squizzato A; Siragusa S; Di Minno G; Ageno W
    Am J Hematol; 2012 Apr; 87(4):384-7. PubMed ID: 22367852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.